Razor Genomics is a molecular diagnostics company based in Brisbane, CA that specializes in providing a molecular stratification test called RiskReveal. This test is designed to identify patients with early-stage non-small cell lung cancer (NSCLC) who may be at low or high risk of recurrence, helping healthcare professionals make informed treatment decisions following surgery.
With a focus on improving patient outcomes, Razor Genomics offers a 14-gene molecular stratification test that has been validated in two independent cohorts, demonstrating its superiority in identifying high-risk patients for mortality from NSCLC. By analyzing the molecular signature of a patient's tumor tissue, RiskReveal provides valuable insights that enable oncologists to optimize treatment post-surgery, ultimately closing the gaps in deciding adjuvant therapy for early-stage adenocarcinoma of the lung.
Generated from the website